HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free All Versions of this Article: 96/6/2161    most recent 01160.2003v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Chardon, K. Articles by Libert, J.-P. Search for Related Content PubMed PubMed Citation Articles by Chardon, K. Articles by Libert, J.-P.

Effect of caffeine on peripheral chemoreceptor activity in premature neonates: interaction with sleep stages

¹Laboratoire d'Environnement Toxique Périnatal et Adaptations Physiologiques et Comportementales (EA2088), Faculté de Médecine, Université de Picardie Jules Verne, F-80036 Amiens; and ²Médecine Néonatale et Réanimation Pédiatrique, University Hospital Center Nord, F-80054 Amiens, France

Submitted 28 October 2003 ; accepted in final form 26 January 2004

Caffeine is widely used for the treatment of apnea in premature neonates. However, the localization of caffeine's target site (central nervous system and/or peripheral chemoreceptors) is not well defined, especially for sleeping neonates whose sleep stages interact with respiratory control. The aim of this study was to assess the activity of the peripheral chemoreceptors in relation to sleep stages in premature neonates treated (or not) with caffeine for idiopathic apnea. Peripheral chemoreceptor activity was assessed in 22 neonates (postconceptional age of 36 ± 1 wk with birth weights ranging from 790 to 1,910 g) by performing a 30-s hyperoxic test during active and quiet sleep. Eleven neonates received caffeine treatment (4.0 ± 0.5 mg·kg^-1·day^-1) and 11 served as controls. For all neonates, the decrease in minute ventilation observed during hyperoxia was greater during active than during quiet sleep. Neonates receiving caffeine showed a significantly greater decrease in ventilation during hyperoxia in both sleep stages, compared with controls (caffeine; -29.7 ± 12.8% vs. control; -22.0 ± 7.4%; F_1,15 = 4.6, P = 0.04). We conclude that caffeine administration increases the effectiveness of chemoreceptor activity. Because sleep stage durations were not affected by the treatment, it is likely that the decrease in apneic episodes typically observed with caffeine therapy is only related to respiratory processes and is independent of the sleep stage organization.

sleep states; hyperoxic test; minute ventilation; sudden infant death syndrome